We can’t show the full text here under this license. Use the link below to read it at the source.
A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
Comparing the Cost and Benefits of Once-Weekly Semaglutide with Other Weekly and Daily Diabetes Treatments in the UK
AI simplified
Abstract
Once-weekly semaglutide 1 mg was superior in achieving treatment goals compared to exenatide ER, dulaglutide, and liraglutide.
- Patients treated with once-weekly semaglutide reached HbA1c targets (< 7.0% and < 7.5%) more effectively than those on other GLP-1 RAs.
- Weight loss targets (≥ 5% reduction) were achieved more frequently with once-weekly semaglutide compared to its comparators.
- In achieving the composite endpoint of HbA1c < 7.0% without weight gain or hypoglycaemia, exenatide ER, dulaglutide, and liraglutide were less efficacious by 50.0%, 21.6%, and 51.3%, respectively.
- The cost of control was similar for all GLP-1 RAs, but once-weekly semaglutide showed superior efficacy-to-cost ratios for all endpoints evaluated.
AI simplified
Key numbers
40.3%
Decrease in Efficacy for HbA1c < 7.0%
Efficacy of exenatide ER 2 mg vs. semaglutide 1 mg
67.3%
Decrease in Efficacy for Weight Loss ≥ 5%
Efficacy of exenatide ER 2 mg vs. semaglutide 1 mg
50.0%
Decrease in Efficacy for Composite Endpoint
Efficacy of exenatide ER 2 mg vs. semaglutide 1 mg for HbA1c < 7.0% without weight gain or hypoglycaemia